400-920-2911 sales@csnpharm.cn
单抗抑制性是一类广泛应用于癌症、免疫学等领域的单克隆抗体。如单克隆抗体与蛋白质特异性结合,从而刺激免疫系统攻击恶性肿瘤细胞,并通过阻断特定的细胞受体阻止肿瘤生长。它们可以抑制CD20、HER、VEGFR、TNF-α等靶点,在非霍奇金淋巴瘤、HER2阳性乳腺癌等疾病中发挥作用。CSNpharm提供多种单抗抑制剂,如Adalimumab、Bevacizumab和Rituximab等,满足您在免疫疾病和癌症领域的研究需求。
货号 | 产品名称 | CAS号 | 描述 |
CSN_mab1010 | Rituximab | 174722-31-7 | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that targets CD20, a B-cell-specific surface antigen. |
CSN_mab1004 | Trastuzumab | 180288-69-1 | Trastuzumab is a humanized IgG1 monoclonal antibody that binds to subdomain IV of HER2 receptor with high affinity and specifcity, inhibiting ligand-independent HER2 signalling and proteolytic cleavage of its extracellular domain. |
CSN_mab1009 | Adalimumab | 331731-18-1 | Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. |
CSN_mab1033 | Infliximab | 170277-31-3 | Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody to TNF. |
CSN_mab1012 | Bevacizumab | 216974-75-3 | Bevacizumab is a recombinant humanized monoclonal immunoglobulin (Ig) G1 antibody that binds to all isoforms and bioactive proteolytic fragments of human vascular endothelial growth factor-A (VEGF), which is essential for both normal and tumor angiogenesis. |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网